Cancer biotech Elicio Therapeutics sets terms for $40 million IPO

Elicio Therapeutics, a Phase 1/2 biotech developing novel immunotherapies for cancer, announced terms for its IPO on Tuesday.

The Cambridge, MA-based company plans to raise $40 million by offering 3.1 million shares at a price range of $12 to $14. At the midpoint of the proposedRead More